Analyst Price Targets — MNPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 9, 2026 10:11 am | Maxwell Skor | Morgan Stanley | $115.00 | $63.40 | TheFly | Monopar Therapeutics initiated with an Overweight at Morgan Stanley |
| November 14, 2025 10:06 am | Chris Raymond | Raymond James | $123.00 | $87.01 | StreetInsider | Raymond James Downgrades Monopar Therapeutics (MNPR) to Outperform |
| October 13, 2025 9:25 am | Etzer Darout | Barclays | $125.00 | $87.82 | TheFly | Monopar Therapeutics initiated with an Overweight at Barclays |
| October 6, 2025 11:26 am | — | Raymond James | $142.00 | $99.39 | TheFly | Monopar Therapeutics price target raised to $142 from $80 at Raymond James |
| October 2, 2025 11:50 am | — | Oppenheimer | $115.00 | $84.73 | TheFly | Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer |
| September 29, 2025 12:13 pm | — | H.C. Wainwright | $105.00 | $76.63 | TheFly | Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright |
| September 25, 2025 11:55 am | Keay Nakae | Chardan Capital | $85.00 | $72.70 | TheFly | Monopar Therapeutics price target raised to $85 from $60 at Chardan |
| September 25, 2025 10:28 am | Biren Amin | Piper Sandler | $95.00 | $72.70 | TheFly | Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler |
| September 24, 2025 8:05 pm | — | BTIG | $104.00 | $73.04 | TheFly | Monopar Therapeutics price target raised to $104 from $87 at BTIG |
| September 9, 2025 10:37 am | Jeet Mukherjee | BTIG | $87.00 | $44.93 | TheFly | Monopar Therapeutics initiated with a Buy at BTIG |
Latest News for MNPR
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately.
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MNPR.
U.S. House Trading
No House trades found for MNPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.